Today we are talking about the decision in Govea v. Medtronic, Inc., 2025 WL 3467214 (C.D. Cal. Nov. 26, 2025). Plaintiff claimed the case was about off-label promotion. But thanks to the court taking judicial notice of PMA supplements, it’s mainly a case about on-label use and a plaintiff who waited far too long
It’s been a been a while – some five years – since we discussed cross-jurisdictional class action tolling. That’s mostly because, aside from the occasional result-oriented atrocity that occurred in the Valsartan MDL, class actions are no longer a top-shelf problem in prescription medical product liability litigation. But it’s still nice to report on a
As we have riffed on before, staying apolitical when discussing the science and law implicated by our posts can be harder than one might expect. That has become increasingly true with regard to litigation over alleged injuries from vaccines, to say nothing of vaccine mandates for public health. It was not terribly
That concept does not feel like it should be controversial in any way. Afterall, at the heart of class action tolling of the statute of limitations, as announced in American Pipe & Construction Co. v. Utah, 414 U.S. 538 (1974), is there must be a pending class action. But the concept gets a little
From its start, the Blog has railed against certain expansions of traditional product liability that could have negative impacts on scientific progress and the availability of good medical products. Innovator liability, first described in Conte back in 2008, is a good example of a bad idea. Its offspring, the so-called duty to innovate
Happy New Year. We are doing that usual January/Janus thing of looking both backwards and forwards. We are gearing up for a massive litigation in 2025, for a couple of trials, and for the January 16 Drug and Device Law webinar on the best and worst cases of 2024. And we’re still finding some 2024
Sometimes bench-bar conferences are actually useful. Last week we wrote a post about a district court’s application of the New York statute of limitations to shut down a product liability lawsuit. The key holding was that the statute of limitations began to run as soon as the plaintiff experienced relevant symptoms. There was no need
(The Butler Snow members of the DDL blog had nothing to do with today’s post.)
Intricate issues of New York law have been in the news lately — but that has been about criminal law. By contrast, New York’s application of the statute of limitations in civil tort cases did not surface on CNN, Fox
For many years, even before the Supreme Court picked up the ball, we have been arguing that “stop selling” theories of liability for alleged injuries from prescription drugs should not be viable. This is not just a preemption issue. Basic product liability principles do not square easily with liability contingent on developing one drug
We don’t usually blog about statute of limitations cases because the issues tend be state and fact specific. But Boyd v. Allergan PLC, 2023 U.S. Dist. LEXIS 115779 (D. Org. Jul. 6, 2023) addresses a fact situation we see repeated often enough in medical device cases that we thought it was worth reporting on.